About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 691369, 12 pages
http://dx.doi.org/10.1155/2012/691369
Review Article

Insulin Resistance in Patients with Chronic Kidney Disease

1Department of Pediatrics, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan
2Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
3Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
4Division of Nephrology, Department of Medicine, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City 242, Taiwan

Received 8 June 2012; Accepted 15 July 2012

Academic Editor: Sandro Massao Hirabara

Copyright © 2012 Min-Tser Liao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. L. Kasiske, B. Chavers, R. Foley, et al., “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, supplement 1, no. 2, pp. S1–S266, 2002.
  2. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Clinical epidemiology of cardiovascular disease in chronic renal disease,” American Journal of Kidney Diseases, vol. 32, no. 5, pp. S112–S119, 1998. View at Scopus
  3. P. Muntner, J. He, L. Hamm, C. Loria, and P. K. Whelton, “Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States,” Journal of the American Society of Nephrology, vol. 13, no. 3, pp. 745–753, 2002. View at Scopus
  4. S. M. Grundy, D. Becker, L. T. Clark, et al., “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Scopus
  5. M. Kurella, J. C. Lo, and G. M. Chertow, “Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2134–2140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Ryu, Y. Chang, H. Y. Woo et al., “Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes,” American Journal of Kidney Diseases, vol. 53, no. 1, pp. 59–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Chen, D. Gu, C. S. Chen et al., “Association between the metabolic syndrome and chronic kidney disease in Chinese adults,” Nephrology Dialysis Transplantation, vol. 22, no. 4, pp. 1100–1106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Thomas, A. R. Sehgal, S. R. Kashyap, T. R. Srinivas, J. P. Kirwan, and S. D. Navaneethan, “Metabolic syndrome and kidney disease: a systematic review and meta-analysis,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2364–2373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. S. Peng, Y. L. Chiu, H. Y. Chen et al., “Decreased high-density lipoprotein cholesterol is associated with inflammation and insulin resistance in non-diabetic haemodialysis patients,” Nephrology, vol. 15, no. 7, pp. 692–699, 2010. View at Scopus
  10. L. C. Zhao, X. D. Zhang, S. X. Liao, H. Y. Wang, D. H. Lin, and H. C. Gao, “A metabonomic comparison of urinary changes in Zucker and GK rats,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 431894, 6 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. S. K. Panchal and L. Brown, “Rodent models for metabolic syndrome research,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 351982, 14 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Kobayashi, K. Maesato, H. Moriya, T. Ohtake, and T. Ikeda, “Insulin resistance in patients with chronic kidney disease,” American Journal of Kidney Diseases, vol. 45, no. 2, pp. 275–280, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Shinohara, T. Shoji, M. Emoto et al., “Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1894–1900, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. B. N. Becker, J. Himmelfarb, W. L. Henrich, and R. M. Hakim, “Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors,” Journal of the American Society of Nephrology, vol. 8, no. 3, pp. 475–486, 1997. View at Scopus
  15. A. K. Cheung, M. J. Sarnak, G. Yan et al., “Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients,” Kidney International, vol. 58, no. 1, pp. 353–362, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. R. A. DeFronzo, A. Alvestrand, and D. Smith, “Insulin resistance in uremia,” Journal of Clinical Investigation, vol. 67, no. 2, pp. 563–568, 1981. View at Scopus
  17. D. Fouque, K. Kalantar-Zadeh, J. Kopple et al., “A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease,” Kidney International, vol. 73, no. 4, pp. 391–398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Barazzoni, G. Gortan Cappellari, M. Zanetti, and G. Guarnieri, “Ghrelin and muscle metabolism in chronic uremia,” Journal of Renal Nutrition, vol. 22, no. 1, pp. 171–175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. R. H. K. Mak and R. A. DeFronzo, “Glucose and insulin metabolism in uremia,” Nephron, vol. 61, no. 4, pp. 377–382, 1992. View at Scopus
  20. H. Pham, K. M. Utzschneider, and I. H. De Boer, “Measurement of insulin resistance in chronic kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 20, no. 6, pp. 640–646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. R. A. DeFronzo, J. D. Tobin, and R. Andres, “Glucose clamp technique: a method for quantifying insulin secretion and resistance,” The American Journal of Physiology, vol. 237, no. 3, pp. E214–223, 1979. View at Scopus
  22. T. Shoji, M. Emoto, and Y. Nishizawa, “HOMA index to assess insulin resistance in renal failure patients,” Nephron, vol. 89, no. 3, pp. 348–349, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. H.-T. Cheng, J.-W. Huang, C.-K. Chiang, C.-J. Yen, K.-Y. Hung, and K.-D. Wu, “Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 4, pp. 1268–1276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Gluba, D. P. Mikhailidis, G. Y. Lip, et al., “Metabolic syndrome and renal disease,” International Journal of Cardiology. In press. View at Publisher · View at Google Scholar
  25. M.-F. Cheng, L.-J. Chen, and J.-T. Cheng, “Decrease of Klotho in the kidney of streptozotocin-induced diabetic rats,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 513853, 7 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. J. W. Rowe, J. B. Young, and K. L. Minaker, “Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man,” Diabetes, vol. 30, no. 3, pp. 219–225, 1981. View at Scopus
  27. U. Özcan, Q. Cao, E. Yilmaz et al., “Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes,” Science, vol. 306, no. 5695, pp. 457–461, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. V. Cybulsky, “Endoplasmic reticulum stressin proteinuric kidney disease,” Kidney International, vol. 77, no. 3, pp. 187–193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. R. Sowers, “Metabolic risk factors and renal disease,” Kidney International, vol. 71, no. 8, pp. 719–720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Saito, H. Sato, N. Iino, and T. Takeda, “Molecular mechanisms of receptor-mediated endocytosis in the renal proximal tubular epithelium,” Journal of Biomedicine & Biotechnology, vol. 2010, Article ID 403272, 7 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Oyama, T. Takeda, H. Hama et al., “Evidence for megalin-mediated proximal tubular uptake of L-FABP, a carrier of potentially nephrotoxic molecules,” Laboratory Investigation, vol. 85, no. 4, pp. 522–531, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. C. E. Winbanks, I. A. Darby, K. J. Kelynack, D. Pouniotis, G. J. Becker, and T. D. Hewitson, “Explanting is an ex vivo model of renal epithelial-mesenchymal transition,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 212819, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Tsimihodimos, E. Dounousi, and K. C. Siamopoulos, “Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment,” American Journal of Nephrology, vol. 28, no. 6, pp. 958–973, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Samuelsson, P. O. Attman, C. Knight-Gibson et al., “Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency,” Journal of the American Society of Nephrology, vol. 9, no. 8, pp. 1482–1488, 1998. View at Scopus
  35. M. Tozawa, K. Iseki, C. Iseki, S. Oshiro, Y. Ikemiya, and S. Takishita, “Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria,” Kidney International, vol. 62, no. 5, pp. 1743–1749, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. R. H. K. Mak, “Insulin resistance in uremia: effect of dialysis modality,” Pediatric Research, vol. 40, no. 2, pp. 304–308, 1996. View at Scopus
  37. S. Kobayashi, S. Maejima, T. Ikeda, and M. Nagase, “Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis,” Nephrology Dialysis Transplantation, vol. 15, no. 1, pp. 65–70, 2000. View at Scopus
  38. A. Esteghamati, H. Ashraf, A. R. Esteghamati et al., “Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: the implication of metabolic syndrome to detect insulin resistance,” Diabetes Research and Clinical Practice, vol. 84, no. 3, pp. 279–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. S. M. Kayacan, A. Yildiz, R. Kazancioglu, S. Sahin, M. S. Sever, and E. Ark, “The changes in serum leptin, body fat mass and insulin resistance after renal transplantation,” Clinical Transplantation, vol. 17, no. 1, pp. 63–68, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. B. B. Nicoletto, G. C. Souza, L. F. Gonçalves, C. Costa, I. S. Perry, and R. C. Manfro, “Leptin, insulin resistance, and metabolic changes 5 years after renal transplantation,” Journal of Renal Nutrition, vol. 22, no. 4, pp. 440–449, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. L. H. Oterdoom, A. P. J. De Vries, R. T. Gansevoort et al., “Determinants of insulin resistance in renal transplant recipients,” Transplantation, vol. 83, no. 1, pp. 29–35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. H. A. Bergrem, T. G. Valderhaug, A. Hartmann, H. Bergrem, J. Hjelmesæth, and T. Jenssen, “Glucose tolerance before and after renal transplantation,” Nephrology Dialysis Transplantation, vol. 25, no. 3, pp. 985–992, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. C. M. Zheng, W. Y. Ma, C. C. Wu, et al., “Glycated albumin in diabetic patients with chronic kidney disease,” Clinica Chimica Acta, vol. 413, no. 19-20, pp. 1555–1561, 2012.
  44. R. Kleemann, M. Van Erk, L. Verschuren et al., “Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance,” PLoS One, vol. 5, no. 1, Article ID e8817, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. J. L. Bailey, B. Zheng, Z. Hu, S. R. Price, and W. E. Mitch, “Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy,” Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1388–1394, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. T. A. Ikizler, “Nutrition, inflammation and chronic kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 17, no. 2, pp. 162–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. V. Menon, D. Rudym, P. Chandra, D. Miskulin, R. Perrone, and M. Sarnak, “Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 1, pp. 7–13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. C. M. Taniguchi, B. Emanuelli, and C. R. Kahn, “Critical nodes in signalling pathways: insights into insulin action,” Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 85–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. Z. Gao, A. Zuberi, M. J. Quon, Z. Dong, and J. Ye, “Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases,” Journal of Biological Chemistry, vol. 278, no. 27, pp. 24944–24950, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. S. W. Lee, G. Dai, Z. Hu, X. Wang, J. Du, and W. E. Mitch, “Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase,” Journal of the American Society of Nephrology, vol. 15, no. 6, pp. 1537–1545, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. D. F. Lee, H. P. Kuo, C. T. Chen et al., “IKKβ suppression of TSC1 function links the mTOR pathway with insulin resistance,” International Journal of Molecular Medicine, vol. 22, no. 5, pp. 633–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Plomgaard, K. Bouzakri, R. Krogh-Madsen, B. Mittendorfer, J. R. Zierath, and B. K. Pedersen, “Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation,” Diabetes, vol. 54, no. 10, pp. 2939–2945, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Plomgaard, C. P. Fischer, T. Ibfelt, B. K. Pedersen, and G. Van Hall, “Tumor necrosis factor-α modulates human in vivo lipolysis,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 2, pp. 543–549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. J. J. Senn, P. J. Klover, I. A. Nowak, and R. A. Mooney, “Interleukin-6 induces cellular insulin resistance in hepatocytes,” Diabetes, vol. 51, no. 12, pp. 3391–3399, 2002. View at Scopus
  55. C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-1-receptor antagonist in type 2 diabetes mellitus,” New England Journal of Medicine, vol. 356, no. 15, pp. 1517–1526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Semple, K. Smith, S. Bhandari, and A. M. L. Seymour, “Uremic cardiomyopathy and insulin resistance: a critical role for Akt?” Journal of the American Society of Nephrology, vol. 22, no. 2, pp. 207–215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Heiss, A. DuChesne, B. Denecke et al., “Structural basis of calcification inhibition by α2-HS glycoprotein/fetuin-A: formation of colloidal calciprotein particles,” Journal of Biological Chemistry, vol. 278, no. 15, pp. 13333–13341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Caglar, M. I. Yilmaz, M. Saglam et al., “Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 1, pp. 61–68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Messa, L. Alberti, G. Como et al., “Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients,” Nephrology Dialysis Transplantation, vol. 22, no. 9, pp. 2724–2725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. C. C. Wang, Y. J. Hsu, C. C. Wu et al., “Serum fetuin-A levels increased following parathyroidectomy in uremic hyperparathyroidism,” Clinical Nephrology, vol. 77, no. 2, pp. 89–96, 2012. View at Scopus
  61. A. M. Hennige, H. Staiger, C. Wicke et al., “Fetuin-A induces cytokine expression and suppresses adiponectin production,” PLoS One, vol. 3, no. 3, Article ID e1765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Y. M. Wang, J. Woo, C. W. K. Lam et al., “Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients,” Nephrology Dialysis Transplantation, vol. 20, no. 8, pp. 1676–1685, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. S. T. Mathews, N. Chellam, P. R. Srinivas et al., “α2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor,” Molecular and Cellular Endocrinology, vol. 164, no. 1-2, pp. 87–98, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Auberger, L. Falquerho, J. O. Contreres et al., “Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity,” Cell, vol. 58, no. 4, pp. 631–640, 1989. View at Scopus
  65. Y. Xu, M. Xu, Y. Bi et al., “Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese,” Atherosclerosis, vol. 216, no. 1, pp. 180–186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Reinehr and C. L. Roth, “Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 11, pp. 4479–4485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. J. H. Ix, C. L. Wassel, A. M. Kanaya et al., “Fetuin-A and incident diabetes mellitus in older persons,” Journal of the American Medical Association, vol. 300, no. 2, pp. 182–188, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. N. Stefan, A. Fritsche, C. Weikert et al., “Plasma fetuin-A levels and the risk of type 2 diabetes,” Diabetes, vol. 57, no. 10, pp. 2762–2767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Song, M. Xu, Y. Bi et al., “Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults,” PLoS One, vol. 6, no. 4, Article ID e19228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. M. M. Rastmanesh, H. A. R. Bluyssen, J. A. Joles, P. Boer, N. Willekes, and B. Braam, “Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease,” European Journal of Pharmacology, vol. 593, no. 1-3, pp. 99–104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. M. M. Rastmanesh, B. Braam, J. A. Joles, P. Boer, and H. A. R. Bluyssen, “Increased SOCS expression in peripheral blood mononuclear cells of end stage renal disease patients is related to inflammation and dialysis modality,” European Journal of Pharmacology, vol. 602, no. 1, pp. 163–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Wesoly, K. Sikorski, C. K. Lee, and H. A. R. Bluyssen, “Suppressor of cytokine signaling and accelerated atherosclerosis in kidney disease,” Acta Biochimica Polonica, vol. 57, no. 3, pp. 251–260, 2010. View at Scopus
  73. S. G. Rønn, N. Billestrup, and T. Mandrup-Poulsen, “Diabetes and suppressors of cytokine signaling proteins,” Diabetes, vol. 56, no. 2, pp. 541–548, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. B. Emanuelli, P. Peraldi, C. Filloux, D. Sawka-Verhelle, D. Hilton, and E. Van Obberghen, “SOCS-3 is an insulin-induced negative regulator of insulin signaling,” Journal of Biological Chemistry, vol. 275, no. 21, pp. 15985–15991, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. K. Ueki, T. Kondo, and C. R. Kahn, “Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms,” Molecular and Cellular Biology, vol. 24, no. 12, pp. 5434–5446, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Rui, M. Yuan, D. Frantz, S. Shoelson, and M. F. White, “SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2,” Journal of Biological Chemistry, vol. 277, no. 44, pp. 42394–42398, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Rieusset, K. Bouzakri, E. Chevillotte et al., “Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients,” Diabetes, vol. 53, no. 9, pp. 2232–2241, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. A. D. Slee, “Exploring metabolic dysfunction in chronic kidney disease,” Nutrition & Metabolism, vol. 9, article 36, 2012. View at Publisher · View at Google Scholar
  79. J. K. Sethi and A. J. Vidal-Puig, “Thematic review series: adipocyte Biology. Adipose tissue function and plasticity orchestrate nutritional adaptation,” Journal of Lipid Research, vol. 48, no. 6, pp. 1253–1262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe, “Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1784–1792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Odamaki, R. Furuya, T. Yoneyama et al., “Association of the serum leptin concentration with weight loss in chronic hemodialysis patients,” American Journal of Kidney Diseases, vol. 33, no. 2, pp. 361–368, 1999. View at Scopus
  82. W. Cheung, P. X. Yu, B. M. Little, R. D. Cone, D. L. Marks, and R. H. Mak, “Role of leptin and melanocortin signaling in uremia-associated cachexia,” Journal of Clinical Investigation, vol. 115, no. 6, pp. 1659–1665, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Ottonello, P. Gnerre, M. Bertolotto et al., “Leptin as a uremic toxin interferes with neutrophil chemotaxis,” Journal of the American Society of Nephrology, vol. 15, no. 9, pp. 2366–2372, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. P. Stenvinkel, “Leptin—a new hormone of definite interest for the nephrologist,” Nephrology Dialysis Transplantation, vol. 13, no. 5, pp. 1099–1101, 1998. View at Publisher · View at Google Scholar · View at Scopus
  85. A. H. Berg, T. P. Combs, X. Du, M. Brownlee, and P. E. Scherer, “The adipocyte-secreted protein Acrp30 enhances hepatic insulin action,” Nature Medicine, vol. 7, no. 8, pp. 947–953, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Yamauchi, J. Kamon, H. Waki et al., “The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity,” Nature Medicine, vol. 7, no. 8, pp. 941–946, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Adamczak, J. Chudek, and A. Wiȩcek, “Adiponectin in patients with chronic kidney disease,” Seminars in Dialysis, vol. 22, no. 4, pp. 391–395, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. D. Teta, “Adipokines as Uremic Toxins,” Journal of Renal Nutrition, vol. 22, no. 1, pp. 81–85, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Ohashi, H. Iwatani, S. Kihara et al., “Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 9, pp. 1910–1917, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. R. S. Ahima, “Linking adiponectin to proteinuria,” Journal of Clinical Investigation, vol. 118, no. 5, pp. 1619–1622, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. R. Ouedraogo, Y. Gong, B. Berzins et al., “Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo,” Journal of Clinical Investigation, vol. 117, no. 6, pp. 1718–1726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. C. Zoccali, F. Mallamaci, G. Tripepi et al., “Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease,” Journal of the American Society of Nephrology, vol. 13, no. 1, pp. 134–141, 2002. View at Scopus
  93. G. Cohen and W. H. Hörl, “Resistin as a cardiovascular and atherosclerotic risk factor and uremic toxin,” Seminars in Dialysis, vol. 22, no. 4, pp. 373–377, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Axelsson, A. Bergsten, A. R. Qureshi et al., “Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance,” Kidney International, vol. 69, no. 3, pp. 596–604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. M. I. Yilmaz, M. Saglam, J. J. Carrero et al., “Serum visfatin concentration and endothelial dysfunction in chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 23, no. 3, pp. 959–965, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Karakan, S. Sezer, F. N. Ö. Acar, and M. Haberal, “The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients,” Renal Failure, vol. 34, no. 6, pp. 732–737, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Yamamoto, A. R. Qureshi, B. Anderstam et al., “Clinical importance of an elevated circulating chemerin level in incident dialysis patients,” Nephrology Dialysis Transplantation, vol. 25, no. 12, pp. 4017–4023, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. L. F. Ramos, A. Shintani, T. A. Ikizler, and J. Himmelfarb, “Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 593–599, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Chonchol and R. Scragg, “25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey,” Kidney International, vol. 71, no. 2, pp. 134–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Levin, G. L. Bakris, M. Molitch et al., “Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease,” Kidney International, vol. 71, no. 1, pp. 31–38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. K. C. R. Baynes, B. J. Boucher, E. J. M. Feskens, and D. Kromhout, “Vitamin D, glucose tolerance anal insulinaemia in elderly men,” Diabetologia, vol. 40, no. 3, pp. 344–347, 1997. View at Publisher · View at Google Scholar · View at Scopus
  103. K. C. Chiu, A. Chu, V. L. W. Go, and M. F. Saad, “Hypovitaminosis D is associated with insulin resistance and β cell dysfunction,” American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 820–825, 2004. View at Scopus
  104. C. Cade and A. W. Norman, “Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo,” Endocrinology, vol. 119, no. 1, pp. 84–90, 1986. View at Scopus
  105. R. H. K. Mak, “1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia,” Kidney International, vol. 53, no. 5, pp. 1353–1357, 1998. View at Publisher · View at Google Scholar · View at Scopus
  106. R. H. K. Mak, “Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients,” Pediatric Nephrology, vol. 6, no. 4, pp. 345–348, 1992. View at Publisher · View at Google Scholar · View at Scopus
  107. R. H. K. Mak, C. Turner, G. B. Haycock, and C. Chantler, “Secondary hyperparathyroidism and glucose intolerance in children with uremia,” Kidney International, vol. 24, no. 16, pp. S-128–S-133, 1983. View at Scopus
  108. M. Akmal, S. G. Massry, and D. A. Goldstein, “Role of parathyroid hormone in the glucose intolerance of chronic renal failure,” Journal of Clinical Investigation, vol. 75, no. 3, pp. 1037–1044, 1985. View at Scopus
  109. I. H. De Boer, “Vitamin D and glucose metabolism in chronic kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 17, no. 6, pp. 566–572, 2008. View at Scopus
  110. I. Lajdova, V. Spustova, A. Oksa, A. Chorvatova, D. Chorvat, and R. Dzurik, “Intracellular calcium homeostasis in patients with early stagesof chronic kidney disease: effects of vitamin D3 supplementation,” Nephrology Dialysis Transplantation, vol. 24, no. 11, pp. 3376–3381, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. K. C. Lu, S. D. Shieh, S. H. Lin et al., “Hyperparathyroidism, glucose tolerance and platelet intracellular free calcium in chronic renal failure,” Quarterly Journal of Medicine, vol. 87, no. 6, pp. 359–365, 1994. View at Scopus
  112. K. Zhang and R. J. Kaufman, “From endoplasmic-reticulum stress to the inflammatory response,” Nature, vol. 454, no. 7203, pp. 455–462, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. M. L. McCaleb, M. S. Izzo, and D. H. Lockwood, “Characterization and partial purification of a factor from uremic human serum that induces insulin resistance,” Journal of Clinical Investigation, vol. 75, no. 2, pp. 391–396, 1985. View at Scopus
  114. J. T. Kielstein and C. Zoccali, “Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?” American Journal of Kidney Diseases, vol. 46, no. 2, pp. 186–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. M. D'Apolito, X. Du, H. Zong et al., “Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 203–213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. Y. W. Chiu, J. D. Kopple, and R. Mehrotra, “Correction of metabolic acidosis to ameliorate wasting in chronic kidney disease: goals and strategies,” Seminars in Nephrology, vol. 29, no. 1, pp. 67–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. K. Kalantar-Zadeh, R. Mehrotra, D. Fouque, and J. D. Kopple, “Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure,” Seminars in Dialysis, vol. 17, no. 6, pp. 455–465, 2004. View at Publisher · View at Google Scholar · View at Scopus
  118. A. P. Goldberg, J. M. Hagberg, and J. A. Delmez, “Metabolic effects of exercise training in hemodialysis patients,” Kidney International, vol. 18, no. 6, pp. 754–761, 1980. View at Scopus
  119. R. H. K. Mak, “Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia,” Journal of Pediatrics, vol. 129, no. 1, pp. 97–104, 1996. View at Scopus
  120. H. Yki-Jarvinen, “Thiazolidinediones,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, 2004. View at Publisher · View at Google Scholar
  121. S. M. Brunelli, R. Thadhani, T. A. Ikizler, and H. I. Feldman, “Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes,” Kidney International, vol. 75, no. 9, pp. 961–968, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Scopus
  123. I. H. De Boer, L. F. Tinker, S. Connelly et al., “Calcium plus vitamin D supplementation and the risk of incident diabetes in the women's health initiative,” Diabetes Care, vol. 31, no. 4, pp. 701–707, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. J. M. Church and G. L. Hill, “Impaired glucose metabolism in surgical patients improved by intravenous nutrition: assessment by the euglycemic-hyperinsulinemic clamp,” Metabolism: Clinical and Experimental, vol. 37, no. 6, pp. 505–509, 1988. View at Scopus
  125. B. C. Melnik, “Leucine signaling in the pathogenesis of type 2 diabetes and obesity,” World Journal of Diabetes, vol. 3, no. 3, pp. 38–53, 2012. View at Publisher · View at Google Scholar
  126. Y. Chen, S. Sood, K. McIntire, R. Roth, and R. Rabkin, “Leucine-stimulated mTOR signaling is partly attenuated in skeletal muscle of chronically uremic rats,” American Journal of Physiology - Endocrinology and Metabolism, vol. 301, no. 5, pp. E873–E881, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. R. H. K. Mak, C. Turner, and T. Thompson, “The effect of a low protein diet with amino acid/keto acid supplements on glucose metabolism in children with uremia,” Journal of Clinical Endocrinology and Metabolism, vol. 63, no. 4, pp. 985–989, 1986. View at Scopus
  128. S. Hadjadj, B. Duly-Bouhanick, A. Bekherraz et al., “Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes,” Diabetes and Metabolism, vol. 30, no. 1, pp. 43–51, 2004. View at Scopus
  129. P. H. Lee, H. Y. Chang, C. W. Tung et al., “Hypertriglyceridemia: an independent risk factor of chronic kidney disease in Taiwanese adults,” American Journal of the Medical Sciences, vol. 338, no. 3, pp. 185–189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. V. Manninen, L. Tenkanen, P. Koskinen et al., “Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment,” Circulation, vol. 85, no. 1, pp. 37–45, 1992. View at Scopus
  131. B. Satirapoj, P. Yingwatanadej, S. Chaichayanon, and J. Patumanond, “Effect of angiotensin II receptor blockers on insulin resistance in maintenance haemodialysis patients,” Nephrology, vol. 12, no. 4, pp. 342–347, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. F. E. Vos, P. J. Manning, W. H. Sutherland, J. B. Schollum, and R. J. Walker, “Anti-inflammatory effect of an insulin infusion in patients on maintenance haemodialysis: a randomized controlled pilot study,” Nephrology, vol. 16, no. 1, pp. 68–75, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. M. Nakazato, N. Murakami, Y. Date et al., “A role for ghrelin in the central regulation of feeding,” Nature, vol. 409, no. 6817, pp. 194–198, 2001. View at Publisher · View at Google Scholar · View at Scopus
  134. S. M. Pöykkö, E. Kellokoski, S. Hörkkö, H. Kauma, Y. A. Kesäniemi, and O. Ukkola, “Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes,” Diabetes, vol. 52, no. 10, pp. 2546–2553, 2003. View at Publisher · View at Google Scholar · View at Scopus
  135. R. Barazzoni, M. Zanetti, M. Stulle et al., “Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients,” Clinical Nutrition, vol. 27, no. 1, pp. 142–149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Barazzoni, X. Zhu, M. Deboer et al., “Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease,” Kidney International, vol. 77, no. 1, pp. 23–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. K. Midtvedt, J. Hjelmesæth, A. Hartmann et al., “Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal,” Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 3233–3239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Chadban, “New-onset diabetes after transplantation - Should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients,” Nephrology Dialysis Transplantation, vol. 23, no. 6, pp. 1816–1818, 2008. View at Publisher · View at Google Scholar · View at Scopus